Abstract
To the Editor: Bullous pemphigoid (BP) is an autoimmune disorder characterized by tense blisters and intense pruritus.1 Initial treatment typically involves the use of topical and systemic corticosteroids, with refractory cases often requiring systemic immunosuppressives or biologics. This systematic review examines treatment outcomes of systemic biologics for BP refractory to other systemic therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
